AGER and prostate cancer: S100P is present in breast, gastric, ovarian, pancreatic, and prostate cancer and colorectal carcinoma [134,135,136], and the S100P-RAGE interaction activates ERK and NF-κB signaling pathways in NIH3T3 cells [137].